Sutro Biopharma (STRO)
Healthcare
Biotechnology
24.20 $
-2.6%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Sutro Biopharma (STRO)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 62.2% of the shares are freely tradable; institutional investors hold 86.8%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
86.8%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
2.3%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
62.2%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
5.6%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
17Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Bvf Inc | 7.55 | 1,251,788 | +0.0 | 03/31/2026 |
| Affinity Asset Advisors, LLC | 6.45 | 1,069,519 | +42.9 | 03/31/2026 |
| Samsara BioCapital, LLC | 6.41 | 1,062,872 | +419.7 | 03/31/2026 |
| Kynam Capital Management, LP | 5.27 | 872,558 | +81.9 | 03/31/2026 |
| Orbimed Advisors, LLC | 4.83 | 801,144 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.35 | 720,442 | +0.0 | 03/31/2026 |
| Eventide Asset Management, LLC | 4.32 | 715,307 | +0.0 | 03/31/2026 |
| Perceptive Advisors LLC | 4.32 | 715,307 | +0.0 | 03/31/2026 |
| RA Capital Management, LLC | 4.32 | 715,307 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Eventide Healthcare & Life Sciences I | 4.32 | 715,307 | +0.0 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.